Narcolepsy and Excessive Daytime Sleepiness in OSA: Strategies to Improving Outcomes
January 26, 2020
In this program, sleep experts Dr. Richard Bogan (Chair), Dr. Yves Dauvilliers, Dr. Kiran Maski, Dr. Paula Schweitzer, and Dr. Michael Thorpy assess traditional and new therapies for treating patients with narcolepsy and EDS in OSA.
CME 2.00 Credits
Narcolepsy in Children: Addressing the Challenges and Improving the Outcomes
January 04, 2020
In this program, pediatric sleep disorder experts Kiran Maski, MD, MPH; Judith Owens, MD, MPH, and Michael Strunc, MD will describe best practices in diagnosis and treatment of narcolepsy.
CME 1.50 Credits
Tailoring LDL-C-Lowering Therapy to Patient Cardiovascular Risk: Identifying Effective Strategies for Patients with Diabetes
November 30, 2019
In this program, a panel of experts will discuss the latest guidelines for managing LDL-C in patients with diabetes, interpret data with nonstatin, LDL-C-lowering therapies, describe improving access to PCSK9 inhibitors and tips for achieving earlier access,
CME 2.00 Credits
Narcolepsy in Children: Overcoming Barriers and Improving Outcomes
October 01, 2019
Narcolepsy in Children
CME 1.00 Credits
Reducing LDL-C and Cardiovascular Risk with Nonstatin Therapy: From Evidence to Practice
July 02, 2019
In this symposium, lipid experts Dr. Robert Giugliano, Dr. Marc Sabatine, and Dr. James Underberg will describe best practices for internists in managing LDL-C and reducing the risk for major cardiovascular events with the addition of nonstatin therapy.
CME 2.00 Credits
Non-Statin Therapy for LDL-Cholesterol Reduction in Primary and Secondary Prevention
May 21, 2019
2.00 Credits
Managing LDL-C to Reduce Cardiovascular Disease Risk: Defining Best Clinical Practice
April 22, 2019
In this program, an expert faculty will discuss the evidence and recommendations for managing LDL-C in patients with ASCVD, familial hypercholesterolemia (FH), diabetes, and those at increased cardiovascular risk without ASCVD.
CME 2.00 Credits
CROSSROADS OF CARE: Facing the Challenges of Heart Failure and Diabetes
April 01, 2019
In this symposium, Dr. James Januzzi and Dr. Mikhail Kosiborod will explain the intertwined relationship between diabetes and HF, and interpret safety and effi cacy data, focusing on HF-related outcomes, from studies with diabetes therapies.
CME 1.00 Credits
Diabetes Therapies Exploring Mechanisms and Role of the Cardiovascular Clinician in CVD Risk Management
March 24, 2019
CME 1.00 Credits
Hyperkalemia and Heart Failure: Recognizing Risks and Exploring Strategies for Improving Outcomes
February 24, 2019
In this program, Dr. Paul Hauptman and Dr. Javed Butler will 1) describe the relationship between RAAS inhibitors, hyperkalemia, and cardiovascular risk, 2) identify goals and treatments for acute, intermediate, and chronic management, and 3) discuss the clinical profi les of, and clinical settings for the use of, new potassium binders.
CME 1.00 Credits